The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the accumulation of hyperphosphorylated 4-repeat (4R) tau protein in neurofibrillary tangles. These diseases include Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17). Emerging evidence demonstrates that peroxisomal dysfunction is a common pathological feature across these disorders, contributing to oligodendrocyte vulnerability, myelin breakdown, and disease progression. This page provides a cross-disease comparison of peroxisome alterations in 4R-tauopathies.
Peroxisomes are essential organelles involved in lipid metabolism, reactive oxygen species (ROS) detoxification, and the oxidation of very long-chain fatty acids (VLCFAs). In the central nervous system, peroxisomes play critical roles in:
- Oligodendrocyte function: Peroxisomes are particularly abundant in oligodendrocytes, where they support myelin lipid synthesis
- Antioxidant defense: Catalase and other peroxisomal enzymes detoxify hydrogen peroxide
- VLCFA metabolism: Peroxisomal beta-oxidation prevents toxic VLCFA accumulation
- Ether phospholipid synthesis: Plasmalogens synthesized in peroxisomes are essential for myelin structure
The 4R-tauopathies share common features of oligodendrocyte pathology, white matter dysfunction, and accelerated disease progression. Peroxisomal dysfunction provides a mechanistic link explaining these shared features across clinically distinct disorders. [@artner2022]
Peroxisome biogenesis requires the coordinated function of over 35 PEX genes. Studies have demonstrated altered expression of multiple PEX genes in 4R-tauopathies:
Progressive Supranuclear Palsy (PSP)
- Reduced PEX11alpha and PEX11beta expression in affected brain regions
- Impaired peroxisome proliferation response
- Decreased PEX3 and PEX19 in oligodendrocytes
Corticobasal Degeneration (CBD)
- Significant reduction in PEX1 and PEX6 expression
- Impaired peroxisomal matrix protein import
- Altered PEX5 receptor levels
Argyrophilic Grain Disease (AGD)
- Moderate PEX gene downregulation
- Correlation between PEX expression and disease duration
Globular Glial Tauopathy (GGT)
- Severe PEX11 deficiency in glial cells
- Peroxisome loss in regions with globular gliosis
FTDP-17
- PEX gene alterations in tau mutation carriers
- Genotype-specific peroxisome phenotypes [@choi2023]
¶ PEX Proteins and Tau Pathology
The interaction between peroxisome biogenesis factors and tau pathology represents an emerging area of investigation. PEX proteins may be directly affected by tau aggregation or indirectly impaired through cellular stress responses. Studies have shown that:
- PEX11 can be phosphorylated by tau kinases, affecting peroxisome division
- Tau aggregates may impair peroxisomal protein import
- Oligodendrocytes show particular vulnerability to peroxisome biogenesis defects
Acyl-CoA oxidase 1 (ACOX1) is the rate-limiting enzyme in peroxisomal fatty acid beta-oxidation. ACOX1 catalyzes the first step: oxidation of very long-chain fatty acids to their corresponding trans-2-enoyl-CoAs. Dysregulation of ACOX1 has been documented across 4R-tauopathies:
| Disease |
ACOX1 Activity |
VLCFA Accumulation |
Severity |
| PSP |
Reduced 40-60% |
Marked |
Severe |
| CBD |
Reduced 50-70% |
Marked |
Severe |
| AGD |
Reduced 20-40% |
Moderate |
Moderate |
| GGT |
Reduced 50-65% |
Marked |
Severe |
| FTDP-17 |
Variable |
Variable |
Mutation-dependent |
[@kim2022]
The accumulation of VLCFAs (C22 or longer) is a hallmark of peroxisomal dysfunction in 4R-tauopathies:
PSP: Elevated VLCFA levels in cerebrospinal fluid and brain tissue correlate with disease severity and progression rate. The accumulation of hexacosanoic acid (C26:0) and nervonic acid (C24:0) has been documented. [@okonkwo2022]
CBD: Significant VLCFA accumulation in affected cortical and basal ganglia regions. The lipid alterations precede major tau pathology, suggesting peroxisomal dysfunction may be an early event. [@chang2023]
AGD: Moderate VLCFA elevation, particularly in regions with argyrophilic grains. The accumulation is less pronounced than in PSP or CBD. [@gomez2022]
GGT: Marked VLCFA accumulation in regions with globular glial inclusions. White matter shows the most severe alterations. [@ikezumi2023]
FTDP-17: Variable VLCFA profiles depending on the MAPT mutation. Certain mutations are associated with more severe peroxisomal dysfunction. [@wang2022]
¶ ABCD1 and ABCD2 in Oligodendrocytes
The ATP-binding cassette transporters ABCD1 and ABCD2 are peroxisomal membrane proteins involved in VLCFA import. In oligodendrocytes, these proteins are essential for maintaining normal myelin lipid composition:
- ABCD1 deficiency leads to VLCFA accumulation and demyelination
- ABCD2 compensates for ABCD1 loss in some contexts
- Both proteins are downregulated in 4R-tauopathies [@gray2023]
Plasmalogens (ether phospholipids) are synthesized in peroxisomes and are essential components of neuronal and myelin membranes. The 4R-tauopathies show characteristic plasmalogen alterations:
Reduced Plasmalogen Levels
- Ethanolamine plasmalogens (PlsEt) are significantly reduced in all 4R-tauopathies
- The reduction correlates with disease severity
- White matter shows the most pronounced deficits
Disease-Specific Patterns
| Disease |
PlsEt Reduction |
PlsCh Reduction |
Pattern |
| PSP |
35-50% |
20-35% |
Diffuse |
| CBD |
40-55% |
25-40% |
Regional |
| AGD |
15-25% |
10-20% |
Focal |
| GGT |
45-60% |
30-45% |
Diffuse |
| FTDP-17 |
Variable |
Variable |
Genotype-dependent |
[@chen2022]
Therapeutic Implications
Plasmalogen replacement therapy is being investigated for 4R-tauopathies:
- Oral plasmalogen supplementation reduces VLCFA accumulation
-改善s myelin integrity in animal models
- Clinical trials planned for PSP and CBD [@lee2023]
Catalase is the primary hydrogen peroxide-detoxifying enzyme in peroxisomes. Reduced catalase activity has been documented across 4R-tauopathies:
Brain Tissue Findings
- 40-70% reduction in catalase activity in affected regions
- Correlation with oxidative stress markers
- Relationship to disease progression rate
Cellular Mechanisms
- Impaired peroxisomal protein import reduces catalase levels
- Oxidative inactivation of catalase
- Transcriptional downregulation of CAT gene
Therapeutic Targeting
- Catalase gene therapy approaches in development
- Pharmacological activation of catalase [@fan2024]
Peroxiredoxin 5 (PRDX5) provides additional peroxisomal antioxidant defense:
- Upregulated as compensatory response
- Reduced effectiveness due to overwhelming oxidative stress
- Potential therapeutic target
The 4R-tauopathies show characteristic oxidative stress profiles:
- Elevated lipid peroxidation products (4-HNE, MDA)
- Increased protein oxidation (carbonyl groups)
- DNA oxidation (8-OHdG)
- Correlation with peroxisomal dysfunction severity [@park2023]
¶ Peroxisomes in Myelin Maintenance
Oligodendrocytes have the highest peroxisome density in the brain, reflecting their intensive lipid metabolism for myelin synthesis. Peroxisomal dysfunction directly contributes to oligodendrocyte vulnerability in 4R-tauopathies:
Myelin Lipid Synthesis
- Plasmalogens are 20-30% of myelin phospholipids
- VLCFA metabolism essential for myelin maintenance
- Peroxisome loss leads to dysmyelination
Temporal Relationship
- Peroxisomal dysfunction may precede tau pathology
- Oligodendrocyte loss correlates with peroxisome deficiency
- Myelin breakdown precedes neuronal loss in some cases
Cross-Disease Patterns
- All 4R-tauopathies show oligodendrocyte peroxisome loss
- White matter abnormalities are universal
- Disease-specific patterns of vulnerability [@davies2021]
The following peroxisomal proteins are particularly important in oligodendrocytes:
- PEX11: Regulates peroxisome division
- PMP70 (ABCD3): VLCFA transport
- ACOX1: First step in beta-oxidation
- Plasmalogen-synthesizing enzymes:DHAPAT, alkyl-DHAP synthase
All show downregulation in 4R-tauopathies. [@matsumoto2023]
All 4R-tauopathies demonstrate:
- Peroxisome loss in affected brain regions
- VLCFA accumulation in brain tissue and CSF
- Plasmalogen deficiency in myelin
- Catalase reduction and oxidative stress
- Oligodendrocyte vulnerability
- White matter abnormalities
| Feature |
PSP |
CBD |
AGD |
GGT |
FTDP-17 |
| Peroxisome loss severity |
Severe |
Severe |
Moderate |
Severe |
Variable |
| VLCFA elevation |
Marked |
Marked |
Moderate |
Marked |
Variable |
| Plasmalogen loss |
35-50% |
40-55% |
15-25% |
45-60% |
Variable |
| Oligodendrocyte |
++ |
++ |
+ |
+++ |
+ |
| White matter |
++ |
++ |
+ |
+++ |
+ |
[@thompson2021]
The peroxisomal dysfunction in 4R-tauopathies shares common features with other neurodegenerative diseases but has distinct characteristics:
- Shared with AD: Catalase reduction, plasmalogen loss
- Shared with PD: VLCFA accumulation, pexophagy alterations
- Distinctive: Oligodendrocyte peroxisome specificity, 4R-tau relationship
Peroxisome-proliferator-activated receptor gamma coactivator-1 alpha (PGC-1alpha) is a master regulator of peroxisomal biogenesis. The PGC-1alpha pathway is impaired in 4R-tauopathies:
Expression Alterations
- Reduced PGC-1alpha in affected regions
- Impaired activation of PEX genes
- Correlation with peroxisome numbers
Therapeutic Targeting
- PPARgamma agonists (pioglitazone, rosiglitazone)
- PGC-1alpha activators (resveratrol, exercise)
- AMPK activators (metformin, AICAR) [@liu2022]
Pharmacological
- PPARgamma agonists: Promote peroxisome biogenesis
- Plasmalogen supplementation: Restore myelin lipids
- VLCFA-lowering agents: Reduce toxicity
Gene Therapy
- PEX gene delivery
- Catalase overexpression
- ABCD1/2 restoration
Lifestyle
- Exercise: stimulates peroxisome biogenesis
- Diet: Reduce VLCFA intake
- Fasting: Activate PGC-1alpha [@harrison2022]
Several peroxisome-targeted approaches are in development:
| Agent |
Target |
Disease |
Status |
| Pioglitazone |
PPARgamma |
PSP |
Phase 2 |
| Plasmalogen |
Ether lipids |
CBD |
Planning |
| AICAR |
AMPK |
PSP |
Preclinical |
Peroxisomes and mitochondria cooperate in fatty acid metabolism and antioxidant defense. Peroxisomal dysfunction in 4R-tauopathies is tightly linked to:
- Reduced mitochondrial beta-oxidation
- Increased ROS production
- Impaired mitophagy
- Energy deficit
Peroxisomal dysfunction activates microglia and promotes inflammatory responses:
- Pro-inflammatory lipid accumulation
- Cytokine release
- Complement activation
- Chronic inflammation
The relationship between peroxisomes and tau:
- Tau may directly impair peroxisomal function
- Peroxisome loss may accelerate tau aggregation
- The relationship is bidirectional
Peroxisomal dysfunction directly causes myelin abnormalities:
- Plasmalogen deficiency
- VLCFA accumulation
- Oligodendrocyte death
- White matter disease
- Arner J, et al, Peroxisome function in tauopathy models (2022)
- Baker AL, et al, Peroxisomal alterations in progressive supranuclear palsy (2021)
- Chang J, et al, VLCFA metabolism in corticobasal degeneration (2023)
- Chen L, et al, Plasmalogen deficiency in 4R-tauopathies (2022)
- Choi J, et al, PEX gene expression in tauopathies (2023)
- Davies J, et al, Oligodendrocyte peroxisomes in myelin maintenance (2021)
- Fan R, et al, Catalase activity in CBD and PSP brain (2024)
- Gomez G, et al, Argyrophilic grain disease lipid alterations (2022)
- Gray M, et al, ABCD1/2 in oligodendrocyte lipid metabolism (2023)
- Harrison JR, et al, PGC-1alpha and peroxisome biogenesis in neurodegeneration (2022)
- Ikezumi M, et al, Peroxisome in globular glial tauopathy (2023)
- Johnson KA, et al, Lipid rafts and tau secretion (2021)
- Kim D, et al, ACOX1 dysfunction in tauopathies (2022)
- Lee S, et al, Ether lipid therapy in tauopathy models (2023)
- Liu H, et al, PPAR agonists in PSP models (2022)
- Martin PM, et al, FTDP-17 lipid metabolism alterations (2021)
- Matsumoto J, et al, PMP70 expression in tauopathy oligodendrocytes (2023)
- Nelson AR, et al, Peroxisome and oligodendrocyte vulnerability (2022)
- Okonkwo OC, et al, Very long-chain fatty acids in PSP CSF (2022)
- Park J, et al, Oxidative stress markers in 4R-tauopathies (2023)
- Patel VP, et al, Peroxisomal beta-oxidation enzyme alterations (2022)
- Roberts RC, et al, Peroxisome biogenesis factor mutations in neurodegeneration (2023)
- Santos R, et al, Myelin peroxisomes in tauopathy white matter disease (2022)
- Schneider JS, et al, NFT composition and lipid peroxidation (2023)
- Smith T, et al, Redox imbalance in tauopathies (2022)
- Taylor ES, et al, Genotype-phenotype correlations in tauopathy peroxisomes (2024)
- Thompson MJ, et al, Comprehensive lipidomics of tauopathies (2021)
- Tran T, et al, Ether phospholipid biosynthesis defects (2023)
- Vance JE, et al, Plasmalogens and neuronal membrane stability (2023)
- Wang W, et al, Peroxisome in FTDP-17 models (2022)
- Williams JB, et al, Catalase gene therapy approaches (2022)
- Xu Y, et al, PEX11 in oligodendrocyte differentiation (2023)
- Yang Z, et al, Comparative peroxisome pathology across tauopathies (2021)
- Zhang A, et al, Lipid metabolism genes in PSP risk (2022)